Overview
- The White House says it reached agreements with Eli Lilly and Novo Nordisk to reduce U.S. prices for GLP-1 drugs including Zepbound, Wegovy and Ozempic.
- Eli Lilly disclosed prices of $449 per month for most doses of a new Zepbound version with $299 for the lowest dose, and an orforglipron pill at $149 for the starter dose and $399 for higher doses pending FDA approval.
- The agreement sets a $245 purchase price for federal programs and creates a $50 monthly copay for eligible Medicare beneficiaries with obesity.
- Novo Nordisk has not announced its pricing under the deal, leaving key details unresolved for Wegovy.
- Doctors say some patients will gain access, yet many remain priced out as states decide on Medicaid coverage, employers reassess benefits, and risky compounded or med-spa products continue to draw demand.